Characteristics of MM patients (samples used in cytotoxicity assays)
| . | NDMM (n = 13) . | RRMM (n = 17) . | DARA-R MM (n = 15) . |
|---|---|---|---|
| Age, median (range), y | 63 (49-86) | 68 (54-77) | 68 (57-80) |
| Male, n (%) | 8 (62) | 12 (71) | 11 (73) |
| LDH, U/L | |||
| Median (range) | 223 (156-490) | 217 (78-1505) | 209 (110-544) |
| Unknown, n (%) | 4 (31) | 0 | 1 (7) |
| Elevated, n (%) | 4 (44) | 6 (35) | 4 (27) |
| eGFR, mL/min/1.73 m2 | |||
| Median (range) | 85 (23-90) | 69 (42-90) | 78 (43-90) |
| Unknown, n (%) | 3 (23) | 0 | 0 |
| <60, n (%) | 1 (10) | 1 (6) | 4 (27) |
| <30, n (%) | 1 (10) | 0 | 0 |
| β2-microglobulin, median (range), mg/L | 3.3 (1.8-10.0) | 4.1 (2.0-6.2) | 4.0 (1.7-7.9) |
| Unknown, n (%) | 1 (8) | 2 (12) | 9 (60) |
| M protein, n (%) | |||
| IgG | 7 (58) | 13 (76) | 9 (60) |
| IgA | 2 (17) | 3 (18) | 3 (20) |
| FLC only | 3 (25) | 1 (6) | 2 (13) |
| Nonsecretor | 0 | 0 | 1 (7) |
| Unknown | 1 (8) | 0 | 0 |
| ISS score, n (%) | |||
| 1 | 6 (50) | ||
| 2 | 4 (33) | ||
| 3 | 2 (17) | ||
| Unknown | 1 (8) | ||
| High-risk cytogenetics,* n (%) | 1 (8) | 6 (38) | 3 (33) |
| Unknown | 0 | 1 (6) | 6 (40) |
| del (17p) | 0 | 4 (25) | 3 (33) |
| t (4;14) | 0 | 2 (13) | 0 |
| t (14;16) | 1 (8) | 0 | 0 |
| Prior lines, median (range) | 0 | 3 (1-8) | 6 (3-16) |
| Prior autologous SCT, n (%) | NA | 11 (65) | 9 (60) |
| Single | 8 (47) | 5 (33) | |
| Double | 3 (18) | 4 (27) | |
| Lenalidomide, n (%) | NA | ||
| Exposed | 15 (88) | 15 (100) | |
| Refractory† | 15 (88) | 15 (100) | |
| Pomalidomide, n (%) | NA | ||
| Exposed | 7 (41) | 7 (47) | |
| Refractory | 6 (35) | 7 (47) | |
| Bortezomib, n (%) | NA | ||
| Exposed | 16 (94) | 14 (93) | |
| Refractory | 4 (24) | 9 (60) | |
| Carfilzomib, n (%) | NA | ||
| Exposed | 5 (29) | 7 (46) | |
| Refractory | 2 (12) | 4 (27) | |
| Ixazomib, n (%) | NA | ||
| Exposed | 1 (6) | 0 | |
| Refractory | 1 (6) | 0 | |
| Daratumumab, n (%) | NA | ||
| Exposed | 0 | 15 (100) | |
| Refractory | 0 | 15 (100) | |
| BCMAxCD3 antibody, n (%) | NA | ||
| Exposed | 0 | 2 (13) | |
| Refractory | 0 | 2 (13) | |
| IMiD,‡ n (%) | NA | ||
| Exposed | 15 (88) | 15 (100) | |
| Refractory | 15 (88) | 15 (100) | |
| PI,§ n (%) | NA | ||
| Exposed | 17 (100) | 15 (100) | |
| Refractory | 6 (35) | 11 (73) | |
| IMiD and PI, n (%) | NA | ||
| Exposed | 15 (88) | 15 (100) | |
| Refractory | 6 (35) | 11 (73) | |
| Triple class,|| n (%) | NA | ||
| Exposed | 0 | 15 (100) | |
| Refractory | 0 | 11 (73) |
| . | NDMM (n = 13) . | RRMM (n = 17) . | DARA-R MM (n = 15) . |
|---|---|---|---|
| Age, median (range), y | 63 (49-86) | 68 (54-77) | 68 (57-80) |
| Male, n (%) | 8 (62) | 12 (71) | 11 (73) |
| LDH, U/L | |||
| Median (range) | 223 (156-490) | 217 (78-1505) | 209 (110-544) |
| Unknown, n (%) | 4 (31) | 0 | 1 (7) |
| Elevated, n (%) | 4 (44) | 6 (35) | 4 (27) |
| eGFR, mL/min/1.73 m2 | |||
| Median (range) | 85 (23-90) | 69 (42-90) | 78 (43-90) |
| Unknown, n (%) | 3 (23) | 0 | 0 |
| <60, n (%) | 1 (10) | 1 (6) | 4 (27) |
| <30, n (%) | 1 (10) | 0 | 0 |
| β2-microglobulin, median (range), mg/L | 3.3 (1.8-10.0) | 4.1 (2.0-6.2) | 4.0 (1.7-7.9) |
| Unknown, n (%) | 1 (8) | 2 (12) | 9 (60) |
| M protein, n (%) | |||
| IgG | 7 (58) | 13 (76) | 9 (60) |
| IgA | 2 (17) | 3 (18) | 3 (20) |
| FLC only | 3 (25) | 1 (6) | 2 (13) |
| Nonsecretor | 0 | 0 | 1 (7) |
| Unknown | 1 (8) | 0 | 0 |
| ISS score, n (%) | |||
| 1 | 6 (50) | ||
| 2 | 4 (33) | ||
| 3 | 2 (17) | ||
| Unknown | 1 (8) | ||
| High-risk cytogenetics,* n (%) | 1 (8) | 6 (38) | 3 (33) |
| Unknown | 0 | 1 (6) | 6 (40) |
| del (17p) | 0 | 4 (25) | 3 (33) |
| t (4;14) | 0 | 2 (13) | 0 |
| t (14;16) | 1 (8) | 0 | 0 |
| Prior lines, median (range) | 0 | 3 (1-8) | 6 (3-16) |
| Prior autologous SCT, n (%) | NA | 11 (65) | 9 (60) |
| Single | 8 (47) | 5 (33) | |
| Double | 3 (18) | 4 (27) | |
| Lenalidomide, n (%) | NA | ||
| Exposed | 15 (88) | 15 (100) | |
| Refractory† | 15 (88) | 15 (100) | |
| Pomalidomide, n (%) | NA | ||
| Exposed | 7 (41) | 7 (47) | |
| Refractory | 6 (35) | 7 (47) | |
| Bortezomib, n (%) | NA | ||
| Exposed | 16 (94) | 14 (93) | |
| Refractory | 4 (24) | 9 (60) | |
| Carfilzomib, n (%) | NA | ||
| Exposed | 5 (29) | 7 (46) | |
| Refractory | 2 (12) | 4 (27) | |
| Ixazomib, n (%) | NA | ||
| Exposed | 1 (6) | 0 | |
| Refractory | 1 (6) | 0 | |
| Daratumumab, n (%) | NA | ||
| Exposed | 0 | 15 (100) | |
| Refractory | 0 | 15 (100) | |
| BCMAxCD3 antibody, n (%) | NA | ||
| Exposed | 0 | 2 (13) | |
| Refractory | 0 | 2 (13) | |
| IMiD,‡ n (%) | NA | ||
| Exposed | 15 (88) | 15 (100) | |
| Refractory | 15 (88) | 15 (100) | |
| PI,§ n (%) | NA | ||
| Exposed | 17 (100) | 15 (100) | |
| Refractory | 6 (35) | 11 (73) | |
| IMiD and PI, n (%) | NA | ||
| Exposed | 15 (88) | 15 (100) | |
| Refractory | 6 (35) | 11 (73) | |
| Triple class,|| n (%) | NA | ||
| Exposed | 0 | 15 (100) | |
| Refractory | 0 | 11 (73) |
Based on the presence of del(17p), t(4;14), and/or t(14;16).
Refractory disease was defined as progressive disease during therapy, no response (less than partial response), or progressive disease within 60 days of stopping treatment, according to the International Uniform Response Criteria for Multiple Myeloma.
Lenalidomide and/or pomalidomide.
Bortezomib, carfilzomib, and/or ixazomib.
At least 1 IMiD plus 1 PI and CD38-targeting antibody.